ASCO GI 2021: Results From the Phase 3 POLO Trial
HCP's Thoughts On Pancreatic Cancer | Knowledge | CREATION.co
LYNPARZA® (olaparib) Efficacy for Metastatic Pancreatic Cancer
NCCN Guidelines Updates: Pancreatic Cancer in: Journal of the National Comprehensive Cancer Network Volume 17 Issue 5.5 (2019)
Pancreatic Cancer - ASCO GI 2021 Highlights - Module - 2021 ASCO GI - Oncology - Clinical Care Options
POLO trial for advanced pancreatic cancer: a | EurekAlert!
ASCO GI 2021: Results From the Phase 3 POLO Trial
BRCA, HRR Deficiency, and PARP Inhibitors - ppt download
FORCE Blog | New PARP Inhibitor Approval for Pancreatic Cancer
Cancers | Free Full-Text | Targeting DNA Damage Repair Mechanisms in Pancreas Cancer
A trial of olaparib for pancreatic cancer that has spread (POLO) | Cancer Research UK
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer | NEJM
Trial results PARP inhibitors in pancreatic cancer | Download Scientific Diagram
Dr. Antonio Calles 🫁🚭 on Twitter: "LBA4 POLO trial: olaparib maintenance in germline BRCA mutant pancreatic adenocarcinoma. Nice data but... PFS as primary endpoint comparing active drug vs no treatment is not
Asco 2019 – Polo reveals an overall survival hole | Evaluate
Diagnostics | Free Full-Text | Surveillance of Individuals with a Family History of Pancreatic Cancer and Inherited Cancer Syndromes: A Strategy for Detecting Early Pancreatic Cancers
A Randomized Study of Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation (The APOLLO Trial) | SpringerLink
Pancreatic Cancer - ASCO GI 2021 Highlights - Module - 2021 ASCO GI - Oncology - Clinical Care Options
Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
